Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Immunol. 2022 Mar 18;208(7):1813–1827. doi: 10.4049/jimmunol.2100700

Figure 7. High Maximum NeoScore has Improved Association with Survival Compared to Mutational Burden.

Figure 7.

Comparison of progression-free survival probability within treatment-naive, cutaneous melanoma patients. All splits between the groups were determined using maximally ranked statistics, and p-values were calculated using a log-rank test. A high tumor mutational burden is (A) not significantly associated with survival in the Van Allen data and (B) significantly associated with decreased survival in the Liu data. Mutational burden directly correlates with neoantigen burden in (C) the Van Allen data and (D) the Liu data. Patients with a high maximum (max.) NeoScore have (E) significantly increased survival in the Van Allen data and (F) significantly increased survival in the Liu dataset.